EHA Annual Meeting Highlights 2015 Live: Advances in Multiple Myeloma Treatment and Management
Release Date: July 20, 2015
Expiration Date: July 20, 2016
Expected time to complete this activity as designed: 60 minutes
There are no fees for participating in or receiving credit for this online activity.
Multiple myeloma (MM) is a cancer of plasma cells that leads to disruption of normal bone marrow function and end organ damage. While still technically considered incurable, life expectancy of multiple myeloma patients has nearly doubled in the past 15 years, and the prognosis for the vast majority of patients, even the elderly, continues to improve. The recent transition of MM from being considered an inevitably fatal malignancy with poor life expectancy to one more characteristic of a chronic disease to be managed has been attributed to the rapid translation of clinical advancements and insights into community practice, and represents one of the greatest clinical success stories in improved cancer treatment and management outcomes today. As a small population cancer, community oncologists who often treat many types of more common malignancies do not see many MM patients and may be challenged to remain current with the latest clinical trial findings that are likely to impact their practice, either immediately, or in the very near future.
Join our Managing Myeloma distinguished team expert and advisory group member Sagar Lonial, MD, at the European Hematology Association (EHA) Annual Meeting 2015, in Vienna Austria, as he discusses the latest clinical findings and insights that are likely to impact multiple myeloma practice today and in the near future with other world-renowned experts including Paul G. Richardson, MD, Antonio Palumbo, MD, and Nikhil Munshi, MD.
Topics of discussion include advances in detecting minimum residual disease and how these may impact practice, the emergence of immunotherapies for MM, the role of carfilzomib-based regimens in relapsed/refractory disease with findings from the ASPIRE and first head-to-head trial of carfilzomib vs bortezomib, the ENDEAVOR trial and optimal dosing schedules of carfilzomib, new targets, next-generation agents and combination strategies including anti-SLAMF7, anti-CD38, and TH-302, and studies that seek to determine cytogenetic markers that predict the risk of progression of MGUS.
This activity is designed for physicians, pharmacists, physician assistants, nurses, and other health care professionals who have an interest in enhancing their clinical skills in multiple myeloma.
Upon completion of this educational activity, participants should be able to:
- Recall recent clinical findings that potentially impact current multiple myeloma treatment and management strategies, or may do so in the near future, throughout the life cycle of the disease.
EHA Annual Meeting Highlights 2015 Live: Advances in Multiple Myeloma Treatment and Management – Sagar Lonial, MD
EHA Annual Meeting Highlights 2015 Live: Advances in Multiple Myeloma Treatment and Management – Sagar Lonial, MD, with Paul G. Richardson, MD
EHA Annual Meeting Highlights 2015 Live: Advances in Multiple Myeloma Treatment and Management – Sagar Lonial, MD, with Nikhil Munshi, MD
EHA Annual Meeting Highlights 2015 Live: Advances in Multiple Myeloma Treatment and Management – Sagar Lonial, MD, with Antonio Palumbo, MD
Instructions for Participation and Credit
This activity is eligible for credit through July 20, 2016. After this date, this activity will expire and no further credit will be awarded.
- Read the target audience, learning objectives, and faculty disclosures.
- You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
- Complete the educational content as designed.
- Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
- Complete the activity evaluation survey to provide feedback and information useful for future programming.
- Certificates for CME and CNE may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.
Sagar Lonial, MD
Vice Chair of Clinical Affairs
Department of Hematology and Medical Oncology
Winship Cancer Institute
Emory University School of Medicine
Dr. Sagar Lonial earned his medical degree from the University of Louisville School of Medicine. He completed his internship and residency at Baylor College of Medicine in Houston, Texas, followed by a fellowship in hematology/oncology at Emory University School of Medicine in Atlanta, Georgia. He is a professor in the Department of Hematology and Medical Oncology at the Winship Cancer Institute of Emory University where he is also the vice chair of clinical affairs, as well as director of the Translational Research for the B-Cell Malignancy Program.
He is involved in numerous professional organizations including the American Society of Clinical Oncology, American Society of Hematology, and the American Society for Blood and Marrow Transplantation. In addition, he serves on the editorial board of the Journal of Clinical Oncology, Leukemia, and is the myeloma editor for Clinical Lymphoma, Myeloma, and Leukemia, and also serves as an invited and ad hoc reviewer for several publications including Blood, and Haematologica, Clinical Cancer Research, The New England Journal of Medicine, and others. Dr. Lonial has authored/coauthored over 200 publications and recently was awarded the Celgene ‘Young Investigator’ Award, the MMRF ‘Top 15 Innovator’ Award, and the MMRC ‘Center of the Year’ award.
Dr. Lonial’s research interest is on combination therapy in B-cell malignancies focusing on myeloma. He is a trained bone marrow transplant physician with an interest in molecular therapy for lymphoma and myeloma. His clinical interests include evaluating the combination of new molecular targeted agents for B-cell tumors as well as target discovery and validation.
Nikhil C. Munshi, MD
Professor of Medicine
Department of Medicine
Harvard Medical School
Dr. Nikhil Munshi received his medical degree from Maharaja Sayajirao University, followed by an internship and residency in internal medicine at Shri Sayaji General Hospital and Maharaja University in India. He then completed an oncology fellowship at Johns Hopkins Oncology Center, and a hematology/oncology fellowship at Indiana University Medical Center. Dr. Munshi is currently professor of medicine in the Department of Medicine at Harvard Medical School, as well as an attending physician at VA Boston Healthcare System and Dana-Farber Cancer Institute.
A diplomate of the American Board of Internal Medicine, Dr. Munshi is also on the Board of Directors of the International Myeloma Society. He is a member of numerous professional associations including the Indian Medical Association, Physician’s Association of India, Indian Association of Clinical Oncology, American Medical Association, American Society of Clinical Oncology, and the American Society of Hematology, among others. In addition, he is on the editorial board of Clinical Lymphoma and Myeloma and Personalized Medicine in Oncology, and is an ad hoc reviewer for numerous professional journals.
Dr. Munshi’s current laboratory research and clinical activities specialize in plasma cell disorders with a focus on understanding oncogenomic changes in myeloma and developing a translational research programs in myeloma. He has also established a Myeloma Initiative at Veterans Administration Hospitals, a comprehensive program bringing together, for the first time, all major VA hospitals across the country to focus on cutting-edge joint clinical studies.
Paul G. Richardson, MD
R.J. Corman Professor of Medicine
Harvard Medical School
Dana-Farber Cancer Institute
Dr. Paul Richardson received his medical degree from the Medical College of St. Bartholomew's Hospital, University of London, and was chief resident at the Royal Marsden Hospital, London. After a clinical fellowship at Baystate Medical Center of Tufts University School of Medicine, he joined Dana-Farber Cancer Institute (DFCI). Dr. Richardson spent five years with the Solid Tumor Autologous Marrow Program, completed a medical residency at Beth Israel Hospital, and joined DFCI’s Jerome Lipper Multiple Myeloma Center, becoming clinical director and most recently, clinical program leader and director of clinical research.
Antonio Palumbo, MD
Associate Professor of Clinical Hematology
Director, Myeloma Unit
Department of Onco-Hematology
University of Torino
Dr. Antonio Palumbo received his medical degree from the University of Torino, Italy, where he served his residency in internal medicine and held a fellowship in hematology/oncology. He is an associate professor of clinical hematology, and director of the Myeloma Unit, Department of Onco-Hematology at University of Torino.
In addition to membership in numerous professional organizations, including the Italian Society of Hematology (SIE), Italian Society of Experimental Hematology (SIES), European Society of Medical Oncology (ESMO), European Society of Hematology (EHA), American Society of Hematology (ASH) and the American Society of Clinical Oncology (ASCO), Dr. Palumbo is on the Board of Directors of the International Myeloma Society. He has authored more than 300 publications in peer-reviewed journals as well numerous abstracts and several textbook chapters. Dr. Palumbo specializes in malignant hematology and medical oncology and has clinical and research interest in plasma cell dyscrasia, his current research focuses on the pathogenesis and treatment of multiple myeloma.
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 1.0 contact hour of Continuing Education Credit. Universal Activity Number: 827-0000-15-044-H01-P. Knowledge-based CPE activity.
In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when registering for a CPE program. Please make sure to provide this information in your Member Profile accessed through the Member Center on the home page of this site.
Accreditation Statement: MediCom Worldwide, Inc., 101 Washington Street, Morrisville, PA 19067 is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.0 contact hour. Program Number: 15-044-014
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.
Dr. Sagar Lonial has received honoraria as a consultant from Bristol-Myers Squibb, Celgene Corporation, Janssen Pharmaceuticals, Inc., Novartis AG, Onyx, Sanofi, and Takeda Oncology.
Dr. Nikhil Munshi has received honoraria as a consultant from Celgene Corporation, Merck & Co., Inc., OncoPep, Pfizer Inc., and Takeda Oncology.
Dr. Antonio Palumbo has received honoraria as a consultant from Amgen Inc., Bristol-Myers Squibb Company, Celgene Corporation, Genmab A/S, Janssen Pharmaceuticals, Inc., Onyx, and Takeda Oncology. He has received additional honoraria from Amgen Inc., Bristol-Myers Squibb, Celgene, Genmab, Janssen, Novartis AG, Onyx, Sanofi and Takeda Oncology.
Dr. Paul Richardson has received honoraria related to formal advisory activities from Bristol-Myers Squibb, Celgene Corporation, Genmab A/S, Johnson & Johnson Services, Inc., Novartis AG, Onyx, and Takeda Oncology.
Planning Committee Disclosures
The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, executive director, and Eugene R. Tombler, PhD, FACME, medical director, oncology, have no relevant financial relationships.
Peer Reviewer Disclosure
In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.
Off-Label Disclosures/Investigational Disclosures
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.
Drs. Lonial, Munshi, Palumbo, and Richardson have indicated that they do intend to discuss off-label uses of drugs, mechanical devices, biologics or diagnostics approved by the US Food and Drug Administration (FDA) for use in the US.
Dr. Lonial has indicated that he does not intend to discuss investigational drugs, mechanical devices, biologics or diagnostics not approved by the FDA for use in the US.
Drs. Munshi, Palumbo, and Richardson have indicated that they do intend to discuss investigational drugs, mechanical devices, biologics or diagnostics not approved by the FDA for use in the US.
MediCom Worldwide, Inc. requires Internet Explorer® version 9.0 or higher, the latest version of Google Chrome, or the latest version of Safari, a computer running Windows® Vista, Windows® 7, or Mac OS X, 512MB of RAM or greater, 1.5 GHZ or faster processor, and a screen resolution of 1024x768 or higher. Certain educational activities may require additional software to view. These activities will be marked with the information and/or links to the required software. That software may include Adobe® Flash® Player, Adobe® Acrobat®, Windows Media® Player, and/or Microsoft® Silverlight™.
If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at email@example.com.
Provided by MediCom Worldwide, Inc.
This activity is supported by educational funding provided by Onyx Pharmaceuticals, an Amgen subsidiary
©2015 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.